Pancreatic Cancer Research

ResearcherMemorial Sloan Kettering Cancer CenterActive in the last 2 years

Luis Alberto Diaz

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7079-8914; OpenAlex author ID A5050789569. Sources: ClinicalTrials.gov.

Their work

Papers
17 (first author 0, last author 3)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
125
Papers, trials and grants by year

2006: 1 trial · 2007: none · 2008: none · 2009: none · 2010: none · 2011: none · 2012: 3 papers · 2013: 2 papers · 2014: 3 papers · 2015: 2 papers · 2016: 1 paper · 2017: 1 paper · 2018: 2 papers · 2019: none · 2020: none · 2021: none · 2022: none · 2023: 1 paper · 2024: none · 2025: 2 papers

Papers 17

  1. Nonoperative Management of Technically Resectable Pancreatic Cancer With Ablative Radiation Therapy. Co-author DOI 10.1001/jamaoncol.2025.0460↗
  2. Perspectives of the medical oncologist regarding adjuvant chemotherapy for pancreatic cancer: An international expert survey and case vignette study. Co-author DOI 10.1016/j.ejso.2024.109544↗
  3. Gemcitabine, Docetaxel, Capecitabine, Cisplatin, Irinotecan as First-line Treatment for Metastatic Pancreatic Cancer. Co-author DOI 10.1158/2767-9764.crc-23-0230↗
  4. Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations. Co-author DOI 10.1158/1078-0432.ccr-17-3099↗
  5. Acquired resistance to immunotherapy in MMR-D pancreatic cancer. Co-author DOI 10.1186/s40425-018-0448-1↗
  6. Long-term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer. Co-author DOI 10.1002/cam4.1104↗
  7. Longer Course of Induction Chemotherapy Followed by Chemoradiation Favors Better Survival Outcomes for Patients With Locally Advanced Pancreatic Cancer. Co-author DOI 10.1097/coc.0000000000000022↗
  8. Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma. Last author DOI 10.1007/s00280-015-2788-6↗
  9. Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients. Co-author DOI 10.1038/ncomms8686↗
  10. The clinical utility of biomarkers in the management of pancreatic adenocarcinoma. Last author DOI 10.1016/j.semradonc.2013.11.007↗
  11. The early detection of pancreatic cancer: what will it take to diagnose and treat curable pancreatic neoplasia? Co-author DOI 10.1158/0008-5472.can-14-0734↗
  12. Baseline hemoglobin-A1c impacts clinical outcomes in patients with pancreatic cancer. Co-author DOI 10.6004/jnccn.2014.0006↗
  13. Understanding the Role of 18Flurodeoxyglucose PET in Predicting Improved Survival in Locally Advanced Pancreatic Cancer. Co-author DOI 10.1016/j.prro.2013.01.090↗
  14. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. Co-author DOI 10.1097/cji.0b013e31829fb7a2↗
  15. A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma. Last author DOI 10.1007/s00280-011-1704-y↗
  16. Evaluation of predictive variables in locally advanced pancreatic adenocarcinoma patients receiving definitive chemoradiation. Co-author DOI 10.1016/j.prro.2011.06.009↗
  17. Genetically defined subsets of human pancreatic cancer show unique in vitro chemosensitivity. Co-author DOI 10.1158/1078-0432.ccr-12-0827↗

Trials 1

  1. One Time Injection of Bacteria to Treat Solid Tumors That Have Not Responded to Standard Therapy Principal investigator NCT00358397↗

Closest collaborators

The 25 strongest of 125 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Daniel A. Laheru · 9 shared papers, 2012–2023 · strength 0.46
  2. Dung Thi Le · 7 shared papers, 2012–2023 · strength 0.38
  3. Eileen Mary O'Reilly · 3 shared papers, 2018–2025 · strength 0.36
  4. Ana De Jesus‐Acosta · 5 shared papers, 2012–2023 · strength 0.32
  5. Anna M. Varghese · 2 shared papers, 2018–2025 · strength 0.27
  6. Kenneth H. Yu · 2 shared papers, 2018–2025 · strength 0.27
  7. Nilofer Saba Azad · 3 shared papers, 2016–2023 · strength 0.26
  8. Ralph H. Hruban · 7 shared papers, 2012–2017 · strength 0.25
  9. Joseph M. Herman · 6 shared papers, 2012–2017 · strength 0.22
  10. Christopher Lee Wolfgang · 6 shared papers, 2012–2017 · strength 0.22
  11. Carla Hajj · 1 shared paper, 2025 · strength 0.20
  12. Zhigang Zhang · 1 shared paper, 2025 · strength 0.20
  13. Marsha Reyngold · 1 shared paper, 2025 · strength 0.20
  14. Abraham Jing-Ching Wu · 1 shared paper, 2025 · strength 0.20
  15. Wei Lü · 1 shared paper, 2025 · strength 0.20
  16. Wungki Park · 1 shared paper, 2025 · strength 0.20
  17. Danny N. Khalil · 1 shared paper, 2025 · strength 0.20
  18. Christopher H. Crane · 1 shared paper, 2025 · strength 0.20
  19. Elliot K. Fishman · 5 shared papers, 2012–2017 · strength 0.19
  20. Helen Catherine Wilbur · 1 shared paper, 2023 · strength 0.17
  21. Hao Wang · 1 shared paper, 2023 · strength 0.17
  22. Katherine M. Bever · 1 shared paper, 2023 · strength 0.17
  23. Robert C. Verdonk · 1 shared paper, 2025 · strength 0.16
  24. Lois A. Daamen · 1 shared paper, 2025 · strength 0.16
  25. Izaak Quintus Molenaar · 1 shared paper, 2025 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.